GT Biopharma Posts Q1 Net Loss of $2.8M With $9M Cash Runway
GT Biopharma reported Q1 2026 results with cash runway of $9M through Q4 2026 and R&D expenses down $700K year-over-year, while SG&A rose $1.6M, driving a $2.8M net loss. Two Phase 1 TriKE® trials are advancing, with GTB-5550 dosing initiated in solid tumors and updates due in H2 2026.
1. Financial Results
The company ended Q1 2026 with $9 million in cash and cash equivalents, projected to fund operations through Q4 2026. R&D expenses declined by $700,000 to $400,000, while SG&A expenses rose by $1.6 million to $2.4 million, resulting in a $2.8 million net loss.
2. GTB-3650 Phase 1 Trial Progress
The Phase 1 dose escalation study of GTB-3650 for relapsed or refractory CD33-positive hematologic malignancies has treated eight patients across four cohorts, with Cohort 4 complete. The trial continues through up to seven cohorts to assess safety, pharmacokinetics, NK cell expansion and preliminary efficacy.
3. GTB-5550 Phase 1 Trial Initiation
The Phase 1 basket trial for GTB-5550 in B7H3-positive solid tumors launched in May 2026, starting with prostate cancer patients in a six-level dose escalation. Subcutaneous dosing will expand into seven tumor types to evaluate tolerability and preliminary anti-tumor activity, with clinical updates expected in the second half of 2026.